The controls for AI in a regulated business depend on the task, data, sector and jurisdiction. Start by listing the systems in use, naming an owner for each and checking the applicable duties before piloting a narrowly defined use case.
TL;DR:
- Define evidence needs for the use case, including model version and relevant decision context. Apply minimisation, access and retention controls; logging every input and output is not a universal requirement or proof of explainability.
- Map inference, storage, support access and onward transfers. Have the responsible reviewer assess applicable processing and transfer duties; knowing locations does not prevent breaches by itself.
- Record model versions and changes, and define validation and revalidation for the intended use. A fixed version alone is not a validated or compliant model.
- Inventory the systems in scope, identify accountable owners and document intended uses, tests and known gaps before deciding on deployment.
- Use staged decisions from a permitted-data pilot to any wider use, with acceptance criteria, review responsibilities and recorded evidence. A phased plan does not avoid scrutiny or establish production readiness.
Table of Contents
- Why AI in regulated industries needs a different build
- Establish Applicable Duties and the Evidence Needed Related reading: The regulatory landscape: what deployers must prove
- Core risks and the controls regulators actually expect
- A phased roadmap from pilot to audit-ready production
- How Pattrn Data applies a governance-first approach
- What AI regulation does to innovation and strategy
- What successful deployment actually looks like
- Where AI regulation is heading next
- Author perspective: three leadership priorities for adopting AI safely
- Book a clarity session or audit with Pattrn Data
- Sources
- FAQ
Why AI in regulated industries needs a different build
Assess the intended task, sector, jurisdiction and data before choosing AI controls. Map API routing, provider access and onward transfers as well as storage; the responsible reviewer must determine which processing and transfer duties apply. Check what existing application logs record before deciding what additional evidence is needed. Missing context, unclear attribution or an unrecorded review should be documented, not assumed to have a fixed legal consequence.
Select integrity and monitoring controls against the evidence and operational needs. Assess explanation quality separately: a stored output or model-generated rationale does not itself explain how a decision was reached.
- Data flows: assess inference, storage, support access and onward transfers against applicable duties
- Evidence records: select necessary fields and record model versions with minimisation, access and retention controls
- Explanation quality: test the basis and limits of the explanation; an accompanying rationale is not proof of the model's reasoning
- Model change: identify fixed versions, vendor updates or learning behaviour and define appropriate retesting
Both changing and fixed models need evidence appropriate to their use. Document updates, test coverage and known limitations; version locking does not establish validity or audit acceptance.
Establish Applicable Duties and the Evidence Needed
For an EU-related use, have the responsible reviewer determine the actor role, system classification, territorial scope and current applicable timetable. The linked Article 101 of the EU AI Act is a starting point for reviewing the specific provision, not a determination of a firm's duties or penalties. Have the responsible professional confirm the current provision, commencement date and any amendments before relying on it.
Pharma and medical-device uses need sector-specific assessment. Before relying on the linked discussion of GxP contexts, confirm the paper, current guidance and relevance of the proposed lifecycle method. Finance teams should likewise confirm their applicable model-risk guidance and obligations. Assess the Bank for International Settlements working paper for relevance; it does not by itself establish the firm's duties.
Evidence categories to assess for the intended review:
- A model inventory with owners named against each system
- Evidence of validation testing and subgroup performance checks
- Applicable processing arrangements and transfer safeguards, as assessed by the responsible data-protection reviewer
- Review records showing the recorded actor, decision and approval, with attribution and coverage limits
Agree retrieval responsibilities and response requirements, and document unavailable evidence. A delay is not automatically a regulatory finding.
Core risks and the controls regulators actually expect
The following five categories can structure an initial review; they are not an exhaustive risk taxonomy or a verified list of controls requested by every examiner.
- Privacy and third-party risk. Map proposed flows, provider and subprocessor access, and permitted data. Have the responsible reviewer determine the contractual, transfer and other safeguards applicable before sending data; no prevalence finding is established here.
- Auditability gaps. Test whether selected evidence fields, version records and custody controls support the review question. Hashes or append-only storage alone do not prove completeness, actor identity or exact reconstruction. Assess the linked engineering-level guidance on shipping AI under compliance constraints against the intended use before adopting its suggestions.
- Explainability failure. Assess the decision context, explanation method and version-specific documentation. Identify outdated model cards and disclose their limits; do not treat a plausible rationale or a model card as evidence that the decision is explained.
- Weak operational governance. Human review gates, clear escalation paths, information barriers between teams handling conflicting mandates, and regular attestation that reviewers are actually reviewing, not rubber-stamping.
- Security and vendor exposure. Supply-chain checks on model providers, adversarial testing before go-live, and an incident playbook that names who does what in the first hour of a failure.
If considering cross-framework mapping, distinguish binding law, a management-system standard and voluntary guidance. Check applicability and gaps independently; no evidence-work saving or equivalence is established by the linked multi-framework governance platforms. Test any proposed runtime rule against allowed and disallowed cases, failures and bypass routes. A rule identifier is not a legal prohibition finding; assess the claims of the linked commercial runtime enforcement products separately.
Pro Tip: Identify the evidence and privacy requirements before selecting logging or explanation tooling. Compare options against the workflow, cost and review needs; no universal priority or effort ranking is established here.
A phased roadmap from pilot to audit-ready production
Use explicit stage decisions to record what was tested and what remains open. A pilot and its evidence do not establish compliance or permission for wider production use.
- Inventory and risk tiering. List every model touching a regulated workflow, its data inputs, and a named human owner. You cannot govern what you have not mapped, and mapping the data going into your AI tools is one inventory prompt. Record omissions and verification limits.
- Design a small, controlled pilot. Pick one workflow, agree acceptance and stop criteria, use synthetic or expressly permitted offline cases, and test review checkpoints and proportionate evidence capture before any live-use decision.
- Validate and document. Run test matrices across subgroups, check for bias in outcomes, and produce a model card that a non-technical auditor could actually read.
- Operationalise. Select monitoring, update and revalidation triggers appropriate to the use; assign an owner and test failed-run handling. A monthly or quarterly cadence is an option, not a universal requirement.
- Package review evidence. Keep the control register, review records, query or test details and version history accessible to authorised reviewers. Test retrieval and document gaps; no examiner acceptance or response-time result is established here.
Two pilot checks to record:
- The pilot scope and stop criteria limited exposure, with observed issues and remediation recorded
- Evidence capture times and custody were recorded; any later reconstruction and its limits were disclosed
Document responsibilities and controls, then test whether they operate. The linked discussion of AI agent governance implementation is a reading pointer, not proof of accountability or a required supplier approach. When assessing how to explain their AI governance approach to a client or regulator, record the evidence available and unresolved gaps rather than assume the exercise identifies them all.
How Pattrn Data applies a governance-first approach
A governance-first approach means mapping the workflow before implementing any tool. This involves locating where decisions are made, setting clear data boundaries around what an AI system can access, maintaining human accountability for judgement at defined checkpoints, and capturing evidence as work happens rather than reconstructing it later.
If considering Pattrn Data support, confirm current session and audit scope, deliverables and total cost. For Copilot, Copilot Studio or Artha, verify data boundaries, approval enforcement and evidence access in the proposed configuration. Product labels and an engagement sequence do not establish discovery of all informal use, regulatory suitability or prevention of data exposure.
Agree the required inventory, evidence records, review workflow and report in the proposal, including exclusions and responsible reviewers. This article does not establish a current deliverable or regulator-ready outcome.
What AI regulation does to innovation and strategy
Include governance, evidence handling and professional review in the implementation plan and budget. Measure the effect on the actual workflow; no deployment-speed, investment or enforcement result follows from that choice alone.
Ask vendors for the evidence needed to assess the intended use, including version documentation, relevant data lineage and configuration limits. Record missing evidence and decide whether the affected use can proceed. Assign technical and professional-review responsibilities without assuming a universal staffing model or a finding from an unspecified systematic review.
For procurement and engagement discussions, determine which evidence and disclosures the client needs. Consult relevant professional guidance, including the linked guidance on how firms should disclose AI use to clients, then confirm applicability with the responsible professional. No competitive or regulatory outcome is established here.
What successful deployment actually looks like
Assess each proposed deployment against its sector, jurisdiction, data and decision risks. A narrow scope, proportionate evidence and accountable review can be tested without treating them as proof of successful scrutiny.
For a finance use, document where a model scores or flags and where a person decides, including authority to challenge or stop an action. Compare the proposed control with the applicable requirements and test it; do not infer regulatory acceptance or an outcome from a control design alone.
For pharma and medical-device uses, have the sector reviewer define applicable validation, lifecycle and change-control requirements. Assess any proposed IVEL approach against the actual product and guidance; neither a fixed model nor the named method establishes approval or a successful rollout.
Possible professional-services pilots include onboarding checks, document-review triage and first-draft reporting, subject to permitted data and professional duties. Assign a named reviewer and acceptance criteria; a pilot example is not evidence of success or a prediction of regulatory action.
Where AI regulation is heading next
Do not plan from a predicted enforcement trajectory. Have the responsible reviewer check current official provisions, commencement dates and any amendments for the intended use. Check the dates and scope for the actual system and actor role rather than relying on a generic deadline.
A cross-framework map may organise evidence, but it does not make laws, standards and voluntary guidance equivalent. Assess each applicable obligation and record gaps. Do not assume a single strictest-regime rule or a cost advantage without examining the use and jurisdictions.
If evaluating runtime controls, test their coverage, rule ownership, failures and bypasses against the intended use. Keep evidence fields and review responsibilities documented so proposed changes can be assessed. No adoption forecast, FDA/EU comparison or future adaptation-cost saving is established here.
Author perspective: three leadership priorities for adopting AI safely
Agree evidence and data-handling requirements before selecting tools. Assign review and escalation authority where the intended use requires it, and test whether the workflow enforces that authority. Budget for monitoring, change review and incident handling beyond the pilot without imposing a universal logging-first sequence.
Rohit
Book a clarity session or audit with Pattrn Data
Before engaging a supplier, agree the workflow, data boundaries, evidence needs and deliverables. Confirm whether the proposed Pattrn Data engagement covers those items; this page does not establish an every-engagement method or a comparative advantage.
If considering an initial review, confirm the current scope and terms of the AI Clarity Session. Compare a scoped review with any proposed SME or enterprise audit against agreed deliverables, exclusions and cost. Do not infer audit readiness or current legal deadlines from the offer. For a proposed workspace, inspect data and approval controls, including those of Artha.
Confirm the proposal and responsibilities before booking, and use synthetic or expressly permitted offline cases for any initial pilot. A session or gap list does not authorise regulated live use.